| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest Diagnostics today reported a 1 percent year-over-year drop in revenues for the fourth quarter, missing the consensus analyst expectation. Revenue for the three months ended Dec. 31, 2018 was $1.84 billion, down from $1.87 billion in the same quarter last year. The consensus Wall Street estimate was $1.88 billion.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2018. "In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the marketplace. Quest is well positioned once again in 2019 to deliver on our commitment to grow revenues and earnings, as our in-network status now extends to approximately 90% of commercially insured lives in the U.S.," said Steve Rusckowski, Chairman, CEO and President. "Our guidance for 2019 reflects significant reimbursement pressure offset by strong volume growth and continued execution of our Invigorate program. I am pleased to report our volumes for the year are off to a good start."
Ms. Wolfson is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. These include the company’s Quanum™ suite of healthcare IT solutions and data analytics, myQuest patient mobile app and portal, and digital engagement for the company’s 2,200 patient service centers.
Quest Diagnostics: Q4 Non-GAAP EPS of $1.36 misses by $0.01; GAAP EPS of $0.92 misses by $0.27.
Quest Diagnostics, the world's leading provider of diagnostic information services, and Houston Healthcare are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services for Houston Medical Center and Perry Hospital.